Referrence

1. Rosenthal J, Brown HL, Harris DT. Stem cell recovery following implementation of an automated cord blood processing system in a high volume laboratory. Biol Blood Marrow Transplant. 2008;14(2):42s.
2. Kurtzberg J, Cairo MS, Fraser JK, et al. Results of the Cord Blood Transplantation (COBLT) Study unrelated donor banking program. Transfusion. 2005;45:842-855.
3. Papassavas AC, Gioka V, Chatzistamatiou T, et al. A strategy of splitting individual high volume cord blood units into two half subunits prior to processing increases the recovery of cells and facilitates ex vivo expansion of the infused hematopoietic progenitor cells in adults. Int Jnl Lab Hem. 2007;1-9.
4. Praught M, Turner T, Brown H. Impact of Anticoagulant and Time from Collection to Processing on Cord Blood Cell Viability and Count. Cytotherapy. 2010;12(S1):46.
5. Harris DT, McGaffey A, Brown H. The effect of collection bag anticoagulant on umbilical cord blood stem cell yield. Transfusion. 2008;48(s2):206A.
6. Baumert B, Grymula K, Pietruszka D, et al. An optimization of hematopoietic stem and progenitor cell isolation for scientific and clinical purposes by the application of a new parameter determining the hematopoietic graft efficacy. Folia Histochem Cytobiol. 2008;46(3):299-305.
7. Brunstein CG, Setubal DC, Wagner JE. Expanding the role of umbilical cord blood transplantation. Br J Haematol. 2007;137(1):20-35.
8. Scaradavou A, Stevens C, Dobrila L, et al. Cord Blood (CB) Unit Mononuclear Cell (MNC) Dose: Effect on Transplantation Outcome and Relevance to Processing Method and CBU Selection. Blood. 2008;112:1969.
9. Fountain D, Ralston M, Higgins N, et al. Liquid nitrogen freezers: a potential source of microbial contamination of hematopoietic stem cell components. Transfusion. 1997;37(6):585-591.
10. Chang Y, Oh W, Choi SJ, et al. Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells Attenuate Hyperoxia-Induced Lung Injury in Neonatal Rats. Cell Transplantation. 2011;18:869-886.
11. Lin YC, Ko TL, Shih YH, et al. Human Umbilical Mesenchymal Stem Cells Promote Recovery After Ischemic Stroke. Stroke. 2011.
12. Kang, Lee YH, Kim MJ, et al. Transplantation of porcine umbilical cord matrix mesenchymal stem cells in a mouse model of Parkinson’s disease. Journal of Tissue Engineering and Regenerative Medicine. 2011.
13. Kim JY, Kim DH, Kim JH, et al. Soluble intracellular adhesion molecule-1 secreted by human umbilical cord blood-derived mesenchymal stem cell reduces amyloid-? plaques. Cell Death and Differentiation. 2011.
14. Zhao Z, Chen Z, Zhao X, et al. Sphingosine-1-phosphate promotes the differentiation of human umbilical cord mesenchymal stem cells into cardiomyocytes under the designated culturing conditions. Journal of Biomedical Science. 2011;18:37.
15. Kim AK, Kim MH, Kim S, et al. Stem-cell Therapy for Peripheral Artery Occlusive Disease. European Journal of Vascular Surgery. 2011.
16. Jung KH, Uhm YK, Lim YJ, et al. Human umbilical cord blood-derived mesenchymal stem cells improve glucose homeostasis in rats with liver cirrhosis. International Journal of Oncology. 2011.
17.Sodian R, Schaefermeier P, Abegg-Zips S, et al. Use of human umbilical cord blood-derived progenitor cells for tissue-engineered heart valves. Ann Thorac Surg. 2010; 89(3):819-28
18. Chua SJ, Bielecki R, Yamanaka N, et al. The effect of umbilical cord blood cells on outcomes after experimental traumatic spinal cord injury. Spine (Phila Pa 1976). 2010;35(16):1520-6.
19. Tark KC, Hong JW, Kim YS, et al. Effects of Human Cord Blood Mesenchymal Stem Cells on Cutaneous Wound Healing in Lepr db Mice. Annals of Plastic Surgery. 2010.
20. Liu Y, Mu R, Wang S, et al. Therapeutic potential of human umbilical cord mesenchymal stem cells in the treatment of rheumatoid arthritis. Arthritis Research & Therapy. 2010;12:R210.
21. Harris D, Schumacher M, LoCascio J, et al. Phenotypic and functional immaturity of human umbilical cord blood T lymphocytes. Proceedings of the National Academy of Sciences. 1992;89:10006-10010.
22. Gluckman E, Rocha V, Boyer-Chammard A, et al. Outcome of cord blood transplantation from related and unrelated donors. Eurocord Transplant Group and the European Blood and Marrow Transplantation Group. N Engl J Med. 1997;337(6):373-381.
23. Bizzetto R, Bonfim C, Rocha V, et al. Outcomes after related and unrelated umbilical cord blood transplantation for hereditary bone marrow failure syndromes other than Fanconi anemia. Haematologica. 2011;96(1):134-41.
24. Butler MG, Menitove JE. Umbilical cord blood banking: an update. J Assist Reprod Genet.2011;28(8):669-76.
25. Marco F, Bureo E, Ortega JJ, et al. High survival rate in infant acute leukemia treated with early high-dose chemotherapy and stem-cell support. Journal of Clinical Oncology.2000;18:3256-3261.
26. McCullough J, Clay M. Reasons for deferral of potential umbilical cord blood donors Transfusion, 2000; 40(1):124-125.
27. Forraz N, McGuckin CP. The umbilical cord: a rich and ethical stem cell source to advance regenerative medicine. Cell Prolif. 2011;44 Suppl 1:60-9.
28. Hao Q, Shah AJ, Thiemann FT, et al. A functional comparison of CD34 + CD38- cells in cord blood and bone marrow. Blood. 1995;86:3745-3753.
29. Morettie, P, Hatlapatka, T, Marten, D, et al. Mesenchymal stromal cells derived from human umbilical cord tissues: primitive cells with potential for clinical and tissue engineering applicaitons. Adv Biochem Engin/Biotechnology. 2010;123:29-54.
30. Rocha V, Wagner JE Jr, Sobocinski KA, et al. Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling. Eurocord and International Bone Marrow Transplant Registry Working Committee on Alternative Donor and Stem Cell Sources. N Engl J Med. 2000;342(25):1846-1854.
31. Behzad-Behbahani A, Pouransari R, Tabei SZ, et al. Risk of viral transmission via bone marrow progenitor cells versus umbilical cord blood hematopoietic stem cells in bone marrow transplantation. Transplant Proc. 2005;37(7):3211-3212.
32. Nietfeld JJ, Pasquini MC, Logan BR, et al. Lifetime probabilities of hematopoietic stem cell transplantation in the U.S. Biol Blood Marrow Transplant. 2008;14(3):316-322.
33. Arora M, Nagaraj S,Wagner JE, et al. Chronic graft-versus-host disease (cGVHD) following unrelated donor hematopoietic stem cell transplantation (HSCT): higher response rate in recipients of unrelated donor (URD) umbilical cord blood (UCB), Biol Blood Marrow Transplant, 2007;13:1145–52.
34. Linden JV, Preti RA, Dracker R. New York state guidelines for cord blood banking. Journal of Hematotherapy. 1997;6:535-41.
35. Broxmeyer HE, Lee MR, Hangoc G, et al. Hematopoietic stem/progenitor cells, generation of induced pluripotent stem cells, and isolation of endothelial progenitors from 21- to 23.5-year cryopreserved cord blood. Blood. 2011;117(18):4773-7
36. Knudtzon S. In vitro growth of granulocytic colonies from circulating cells in human cord blood. Blood. 1974;43(3):357-61.
37. Harris DT. Collection, processing and banking of umbilical cord blood for clinical use. The Journal of the Bellevue Obstetrical and Gynecological Society. 2002;18:13-21.
38. McGuckin CP, Forraz N, Baradez MO, et al. Production of stem cells with embryonic characteristics from human umbilical cord blood. Cell Prolif. 2005;38(4):245-55.
39. Perlow JH. Patient’s knowledge and understanding of umbilical cord blood banking. Journal of Reproductive Medicine. 2006;51(8):642-8.
40. Hayani A, Lampeter E, Viswanatha D, et al. First report of autologous cord blood transplantation in the treatment of a child with leukemia. Pediatrics. 2007;119:296-300.